EZH1 Antibody (YA4400)
(Synonyms: KMT6B)EZH1 Antibody (YA4400) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to EZH1.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
WB, FC, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in PBS with 0.05% sodium azide
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|
| Dilution Ratio | 1:500-1:2000 | 1:200-1:400 | 1:10000 |
Product Details
EZH1 Antibody (YA4400) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to EZH1.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 80-95 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 85 kDa
Purified recombinant fragment of human EZH1 (AA: 135-294) expressed in E. Coli.
affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS with 0.05% sodium azide
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
EZH1 is a PRC2 catalytic homolog that methylates histone H3 lysine 27 and supports transcriptional repression in chromatin regulation[1]. Mechanistically, EZH1 colocalizes with H3K27me3 and preserves this mark on development-related genes when EZH2 is absent, linking EZH1 to embryonic stem cell identity and pluripotency execution[1]. In adult models, EZH1 maintains hematopoietic stem cells in a slow-cycling, undifferentiated state and protects them from senescence-like cell-cycle arrest[2]. Compared with EZH2, EZH1 forms similar PRC2 complexes but represses chromatin through a distinct mechanism, because PRC2-EZH2 strongly catalyzes H3K27me2/3 whereas PRC2-EZH1 more directly compacts chromatin[3]. Functional redundancy is context-dependent, as EZH1 and EZH2 jointly sustain H3K27 trimethylation in mouse skin, where double targeting abolishes H3K27me3 and disrupts hair follicle homeostasis and wound repair[4]. In cancer research, EZH1/2 dual inhibitors provide experimental tools to test whether simultaneous EZH1 and EZH2 blockade suppresses H3K27me3 more effectively than EZH2-selective inhibition[5]. Valemetostat studies further support EZH1/2 inhibition as a translational model in relapsed or refractory adult T-cell leukemia/lymphoma[6].
-
Subcellular Localization
Nucleus
-
Isoforms & Post-Translational Modification
Q92800 has 5 isomers: Q92800-1: 85271 Da (predicted); Q92800-2: 86025 Da (predicted); Q92800-3: 80699 Da (predicted); Q92800-4: 76952 Da (predicted); Q92800-5: 68961 Da (predicted).
-
Subunit
Component of the PRC2/EED-EZH1 complex, which includes EED, EZH1, SUZ12, RBBP4 and AEBP2 (PubMed:19026781). The PRC2/EED-EZH1 is less abundant than the PRC2/EED-EZH2 complex, has weak methyltransferase activity and compacts chromatin in the absence of the methyltransferase cofactor S-adenosyl-L-methionine (SAM) (PubMed:19026781). Interacts with EZHIP; the interaction blocks EZH1 methyltransferase activity (PubMed:31451685)
-
SwissProt ID
-
Synonyms
KMT6B
Documentation
References
[1]. Shen X, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell. 2008 Nov 21;32(4):491-502. [Content Brief]
[2]. Hidalgo I, et al. Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. Cell Stem Cell. 2012 Nov 2;11(5):649-62. [Content Brief]
[3]. Margueron R, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell. 2008 Nov 21;32(4):503-18. [Content Brief]
[4]. Ezhkova E, et al. EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev. 2011 Mar 1;25(5):485-98. [Content Brief]
[5]. Sato T, et al. c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice. Cancer Sci. 2017 Nov;108(11):2156-2165. [Content Brief]
[6]. Izutsu K, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood. 2023 Mar 9;141(10):1159-1168. [Content Brief]